Edwards Lifesciences (EW) Common Equity (2009 - 2026)

Edwards Lifesciences' Common Equity history runs 18 years deep, the most recent figure standing at $10.3 billion for Q1 2026.

• In Q1 2026, Common Equity rose 1.33% year-over-year to $10.3 billion; the TTM figure through Mar 2026 stood at $10.3 billion (up 1.33% YoY), while the FY2025 annual figure was $10.3 billion, up 2.73% from the prior year.
• Common Equity was $10.3 billion for Q1 2026 at Edwards Lifesciences, roughly flat from $10.3 billion in the prior quarter.
• In the past five years, Common Equity ranged from a high of $10.6 billion in Q2 2025 to a low of $5.8 billion in Q4 2022.
• Historically, Common Equity has averaged $8.0 billion across 5 years, with a median of $7.2 billion in 2024.
• The sharpest annual moves came in 2022 and 2024: Common Equity slipped 0.5% in 2022, then soared 49.76% in 2024.
• A 5-year view of Common Equity shows it stood at $5.8 billion in 2022, then climbed by 15.72% to $6.7 billion in 2023, then soared by 49.76% to $10.1 billion in 2024, then grew by 2.73% to $10.3 billion in 2025, then slipped by 0.1% to $10.3 billion in 2026.
• The last three Common Equity figures came in at $10.3 billion (Q1 2026), $10.3 billion (Q4 2025), and $10.2 billion (Q3 2025), per Business Quant data.